• Mansour Gergi, Andrew Goodwin, Kalev Freeman, Christos Colovos, and Oksana Volod.
• Department of Medicine/Division of Hematology Oncology.
• Blood Coagul. Fibrinolysis. 2021 Apr 1; 32 (3): 225-228.

AbstractCoronavirus disease 2019 (COVID-19)-associated coagulopathy is unusual, poorly defined and is linked with significant hypercoagulability and microthrombotic and macrothrombotic complications leading to worse outcomes and higher mortality. Conventional coagulation assays do not always actively reflect these derangements and might fail to detect this coagulopathy. Viscoelastic hemostatic assays (VHA) provide a possible tool that adds to conventional coagulation assays in identifying this hypercoagulable state. VHA has been mostly used in surgery and trauma but it's still not well defined in sepsis patients with lack of large randomized trials. Few studies described VHA findings in patients with COVID-19 showing significant hypercoagulability and fibrinolysis shutdown. Clinicians taking care of these patients might have little experience interpreting VHA results. By reviewing the available literature on the use of VHA in sepsis, and the current knowledge on COVID-19-associated coagulopathy we provide clinicians with a practical guide on VHA utilization in patients with COVID-19.Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

14 keywords...

hide…